Aviko Radiopharmaceuticals

Executive Summary

Aviko Radiopharmaceuticals is a Houston-based private biotech company founded in 2019, pioneering boron-based radiopharmaceuticals for Boron Neutron Capture Therapy (BNCT) in solid tumors. BNCT is a precision oncology modality that combines a boron-containing drug with neutron irradiation to selectively destroy cancer cells while sparing healthy tissue. Aviko aims to develop novel boron delivery agents that improve tumor targeting and safety, addressing limitations of current BNCT compounds. The company is building partnerships with drug developers and medical centers to advance its platform and create an ecosystem for BNCT adoption. As an early-stage firm with no disclosed funding or pipeline details, Aviko is pre-revenue and likely in preclinical development. It faces the typical risks of radiopharmaceutical development, including regulatory hurdles, manufacturing challenges, and clinical validation. However, BNCT has garnered renewed interest due to recent accelerator technology advancements, positioning Aviko to capitalize on a niche but growing market. Success will depend on securing capital, proving preclinical efficacy, and forming strategic collaborations to access neutron sources and clinical sites.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round60% success
• Q2 2026Preclinical Proof-of-Concept Data Release50% success
• Q4 2026Strategic Partnership with BNCT Center or Pharma40% success